Kim H, Park H
Toxicol Res. 2025; 41(2):105-121.
PMID: 40013078
PMC: 11850699.
DOI: 10.1007/s43188-024-00275-8.
Llabjani V, Siddique M, Macos A, Abouzid A, Hoti V, Martin F
In Vitro Model. 2025; 1(6):423-435.
PMID: 39872618
PMC: 11756440.
DOI: 10.1007/s44164-022-00027-8.
Gomez-Mercader A, Monzon-Atienza L, Montero D, Bravo J, Acosta F
Cells. 2024; 13(21.
PMID: 39513924
PMC: 11544930.
DOI: 10.3390/cells13211818.
Ueyama-Toba Y, Tong Y, Yokota J, Murai K, Hikita H, Eguchi H
iScience. 2024; 27(9):110778.
PMID: 39280628
PMC: 11401167.
DOI: 10.1016/j.isci.2024.110778.
Xie R, Pal V, Yu Y, Lu X, Gao M, Liang S
Biomaterials. 2023; 304:122408.
PMID: 38041911
PMC: 10843844.
DOI: 10.1016/j.biomaterials.2023.122408.
Three-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models.
Urzi O, Gasparro R, Costanzo E, De Luca A, Giavaresi G, Fontana S
Int J Mol Sci. 2023; 24(15).
PMID: 37569426
PMC: 10419178.
DOI: 10.3390/ijms241512046.
Multicellular Liver Organoids: Generation and Importance of Diverse Specialized Cellular Components.
Ietto G, Iori V, Gritti M, Inversini D, Costantino A, Izunza Barba S
Cells. 2023; 12(10).
PMID: 37408262
PMC: 10217024.
DOI: 10.3390/cells12101429.
Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
Chen Y, Liu Y, Chen S, Zhang L, Rao J, Lu X
Front Immunol. 2023; 14:1180184.
PMID: 37334366
PMC: 10272526.
DOI: 10.3389/fimmu.2023.1180184.
Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI.
Stern S, Wang H, Sadrieh N
Cells. 2023; 12(11).
PMID: 37296597
PMC: 10253021.
DOI: 10.3390/cells12111476.
Advancements in Research on Constructing Physiological and Pathological Liver Models and Their Applications Utilizing Bioprinting Technology.
Ming Z, Tang X, Liu J, Ruan B
Molecules. 2023; 28(9).
PMID: 37175094
PMC: 10180184.
DOI: 10.3390/molecules28093683.
Liver three-dimensional cellular models for high-throughput chemical testing.
Yang S, Ooka M, Margolis R, Xia M
Cell Rep Methods. 2023; 3(3):100432.
PMID: 37056374
PMC: 10088249.
DOI: 10.1016/j.crmeth.2023.100432.
Light-controlled scaffold- and serum-free hard palatal-derived mesenchymal stem cell aggregates for bone regeneration.
Jiang Z, Li N, Shao Q, Zhu D, Feng Y, Wang Y
Bioeng Transl Med. 2023; 8(1):e10334.
PMID: 36684075
PMC: 9842060.
DOI: 10.1002/btm2.10334.
Physiologically relevant microsystems to study viral infection in the human liver.
McDuffie D, Barr D, Agarwal A, Thomas E
Front Microbiol. 2022; 13():999366.
PMID: 36246284
PMC: 9555087.
DOI: 10.3389/fmicb.2022.999366.
Direct Differentiation of Human Embryonic Stem Cells to 3D Functional Hepatocyte-like Cells in Alginate Microencapsulation Sphere.
Xie X, Zhou X, Liu T, Zhong Z, Zhou Q, Iqbal W
Cells. 2022; 11(19).
PMID: 36231094
PMC: 9562699.
DOI: 10.3390/cells11193134.
Bioprinting of a Hepatic Tissue Model Using Human-Induced Pluripotent Stem Cell-derived Hepatocytes for Drug-Induced Hepatotoxicity Evaluation.
He J, Wang J, Pang Y, Yu H, Qin X, Su K
Int J Bioprint. 2022; 8(3):581.
PMID: 36105133
PMC: 9468961.
DOI: 10.18063/ijb.v8i3.581.
The Potential Clinical Use of Stem/Progenitor Cells and Organoids in Liver Diseases.
Nikokiraki C, Psaraki A, Roubelakis M
Cells. 2022; 11(9).
PMID: 35563716
PMC: 9101582.
DOI: 10.3390/cells11091410.
Current Status and Challenges of Human Induced Pluripotent Stem Cell-Derived Liver Models in Drug Discovery.
Tricot T, Verfaillie C, Kumar M
Cells. 2022; 11(3).
PMID: 35159250
PMC: 8834601.
DOI: 10.3390/cells11030442.
HiPSC-Derived Hepatocyte-like Cells Can Be Used as a Model for Transcriptomics-Based Study of Chemical Toxicity.
Ghosh S, De Smedt J, Tricot T, Proenca S, Kumar M, Nami F
Toxics. 2022; 10(1).
PMID: 35051043
PMC: 8780865.
DOI: 10.3390/toxics10010001.
Current Perspective: 3D Spheroid Models Utilizing Human-Based Cells for Investigating Metabolism-Dependent Drug-Induced Liver Injury.
Cox C, Lynch S, Goldring C, Sharma P
Front Med Technol. 2022; 2:611913.
PMID: 35047893
PMC: 8757888.
DOI: 10.3389/fmedt.2020.611913.
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.
Segovia-Zafra A, Di Zeo-Sanchez D, Lopez-Gomez C, Perez-Valdes Z, Garcia-Fuentes E, Andrade R
Acta Pharm Sin B. 2022; 11(12):3685-3726.
PMID: 35024301
PMC: 8727925.
DOI: 10.1016/j.apsb.2021.11.013.